Maintenance of biologic-free remission with naproxen or no treatment in patients with early, Active Axial Spondyloarthritis: Results from a 6-month, randomised, open-label follow-up study, INFAST Part 2

Annals of the Rheumatic Diseases

Volumn 73, Issue 1, 2014, Pages 108-113

  Sieper, J ^a   Lenaerts, J ^b   Wollenhaupt, J ^c   Rudwaleit, M ^a   Mazurov, V I ^d   Myasoutova, L ^e   Park, S ^f   Song, Y ^g   Yao, R ^h   Chitkara, D ^h   Vastesaeger, N ⁱ  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Reuma Instituut   (Belgium)

^c Epilepsy Center for Children and Adolescents   (Germany)

^d NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

^e KAZAN STATE MEDICAL UNIVERSITY   (Russian Federation)

^f The Catholic University of Korea   (South Korea)

^g Seoul National University   (South Korea)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ Merck Sharp and Dohme   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; NAPROXEN; PLACEBO;

ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BATH ANKYLOSING SPONDYLITIS METROLOGY INDEX; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; EUROQOL 5D HEALTH QUESTIONNAIRE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INTERVERTEBRAL DISK HERNIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHINITIS; SPONDYLARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; YOUNG ADULT;

NSAIDS; SPONDYLOARTHRITIS; TNF-ALPHA;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NAPROXEN; PLACEBOS; REMISSION INDUCTION; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84889681652     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203460     Document Type: Article

References (16)

1. van der Heijde D, Sieper J, Maksymowych WP, et al. Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-8.
2. Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6. (Pubitemid 37409337)
3. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91. (Pubitemid 40216323)
4. Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondyloarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008;58:1981-91. (Pubitemid 351988090)
5. Barkham N, Keen H, Coates L, et al. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009;60:946-54.
6. Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 2014;73:101-7.
7. Klarenbeek NB, van der Kooij SM, Güler-Yüksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011;70:315-19.
8. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis, RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010;69:1286-91.
9. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009;68:914-21.
10. Baraliakos X, Listing J, Brandt J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005;7:R439-44.
11. Heldmann F, Brandt J, van der Horst-Bruinsma IE, et al. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2011;29:672-80.
12. Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013;72:815-22.
13. Song I-H, Hermann KG, Haibel H, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011;70:590-6.
14. Song IH, Althoff CE, Haibel H, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis 2012;71:1212-15.
15. Rudwaleit M, Schwarzlose S, Hilgert ES, et al. MRI in predicting a major clinical response to anti- tumour necrosis factor-treatment in ankylosing spondylitis. Ann Rheum Dis 2008;67:1276-81.
16. Finckh A, Liang MH, van Herckenrode CM, et al. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 2006;55:864-7